ESC Premium Access

Large number of real world evidence studies confirmed effectiveness and safety in treatment with Val/Aml and Val/Aml/HCT worldwide across various ethical groups, disease severities and co-morbidities

Congress Presentation

About the speaker

Doctor Kirstin Stricker

Novartis Pharma, Basel (Switzerland)
0 follower

6 more presentations in this session

Combination of valsartan/amlodipine is more effective than bisoprolol/hydrochlorothiazide on reduction of blood pressure variability in patients with moderate or severe hypertension after control

Speaker: Professor S. Shehata (El-Minya, EG)

Thumbnail

Antihypertensive treatment effect on 24h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment

Speaker: Professor S. Omboni (Solbiate Arno, IT)

Thumbnail

Six-year trends in antihypertensive monotherapy: focus on blood pressure control and originals/generics ratio

Speaker: Professor A. Konradi (Saint Petersburg, RU)

Thumbnail

Which is the best choice? One year persistence of ramipril, ramipril/amlodipin free and fixed dose combination therapy in hypertension

Speaker: Doctor G. Simonyi (Budapest, HU)

Thumbnail

Effect of antihypertensive treatment with indapamide on bone metabolism in patients with arterial hypertension and osteoarthritis

Speaker: Mrs K. Simbirtseva (Kyiv, UA)

Thumbnail

Access the full session

Poster session 2 - Hypertension drug treatment

Speakers: Doctor K. Stricker, Professor S. Shehata, Professor S. Omboni, Professor A. Konradi, Doctor G. Simonyi...
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb